Copper and iron in Alzheimer's disease: A systematic review and its dietary implications

British Journal of Nutrition

Volumn 107, Issue 1, 2012, Pages 7-19

  Loef, Martin ^a,b   Walach, Harald ^a,b  

^a EUROPEAN UNIVERSITY VIADRINA   (Germany)

^b Samueli Institute   (Germany)

Author keywords

Alzheimer's disease; Copper; Iron

Indexed keywords

8 QUINOLINOL DERIVATIVE; CHOLINESTERASE INHIBITOR; CLIOQUINOL; COPPER; DEFEROXAMINE; DONEPEZIL; IRON; PBT 2; PENICILLAMINE; PLACEBO; SATURATED FATTY ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AUTOPSY; BRAIN LEVEL; CASE CONTROL STUDY; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COPPER BLOOD LEVEL; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG MEGADOSE; HUMAN; LIPID DIET; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; ANIMALS; CHELATION THERAPY; COPPER; DIETARY FATS; HUMANS; IRON, DIETARY; RISK FACTORS;

EID: 84855436822     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S000711451100376X     Document Type: Review

References (189)

1. Mertz W (1981) The essential trace elements. Science 213, 1332-1338. (Pubitemid 12243630)
2. Muñoz M, Villar I & García-Erce JA (2009) An update on iron physiology. World J Gastroenterol 15, 4617-4626.
3. Linder M & Hazegh-Azam M (1996) Copper biochemistry and molecular biology. Am J Clin Nutr 63, 797S-811S. (Pubitemid 26126602)
4. Kehrer JP (2000) The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 149, 43-50. (Pubitemid 30645786)
5. Rayman MP (2000) The importance of selenium to human health. Lancet 356, 233-241. (Pubitemid 30446984)
6. Brewer GJ (2010) Risks of copper and iron toxicity during aging in humans. Chem Res Toxicol 23, 319-326.
7. Brewer GJ (2007) Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp Biol Med 232, 323-335. (Pubitemid 46203301)
8. Altamura S & Muckenthaler MU (2009) Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 16, 879-895.
9. Weinberg ED & Miklossy J (2008) Iron withholding: a defense against disease. J Alzheimers Dis 13, 451-463. (Pubitemid 352039024)
10. Gerlach M, Ben-Shachar D, Riederer P, et al. (1994) Altered brain metabolism of iron as a cause of neurodegen-erative diseases J Neurochem 63, 793-807. (Pubitemid 24266591)
11. Gaggelli E, Kozlowski H, Valensin D, et al. (2006) Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis. Chem Rev 106, 1995-2044.
12. Hallgren B & Sourander P (1958) The effect of age on the non-haemin iron in the human brain. J Neurochem 3, 41-51.
13. Bartzokis G, Beckson M, Hance DB, et al. (1997) MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging 15, 29-35. (Pubitemid 27143746)
14. Zecca L, Gallorini M, Schünemann V, et al. (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neuro-chem 76, 1766-1773. (Pubitemid 32221116)
15. Speziali M & Orvini E (2003) Metals distribution and regionalization in the brain. In Metal Ions and Neurodegen-erative Disorders, pp. 15-65 [P Zatta, editor]. Singapore: World Scientific Publishing Co Inc.
16. Bush AI (2003) The metallobiology of Alzheimer's disease. Trends Neurosci 26, 207-214. (Pubitemid 36412003)
17. Watt NT, Whitehouse IJ & Hooper NM (2011) The role of zinc in Alzheimer's disease. Int J Alzheimers Dis 2011, 971021.
18. Alzheimer's Disease International (2009) World Alzheimer Report. http://www.alz.co.uk/research/files/WorldAlzheimer Report.pdf (cited 2010 01·09·2010)
19. WHO (2009) WHO World Alzheimer Report. Geneva: WHO.
20. Brookmeyer R, Johnson E, Ziegler-Graham K, et al. (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191. (Pubitemid 46825511)
21. Campion D, Dumanchin C, Hannequin D, et al. (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 65, 664-670. (Pubitemid 30468710)
22. Brouwers N, Sleegers K & Van Broeckhoven C (2008) Molecular genetics of Alzheimer's disease: an update. Ann Med 40, 562-583.
23. Butterfield DA, Castegna A, Pocernich CB, et al. (2002) Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem 13, 444-461. (Pubitemid 34876979)
24. Scarmeas N, Stern Y, Tang M, et al. (2006) Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 59, 912-921. (Pubitemid 43830923)
25. Solfrizzi V, Panza F & Capurso A (2003) The role of diet in cognitive decline. J Neural Transm 110, 95-110. (Pubitemid 36135557)
26. Braak H & Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239-259.
27. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. (Pubitemid 39061671)
28. Bush AI & Tanzi RE (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5, 421-432. (Pubitemid 351952485)
29. Lovell M, Robertson J, Teesdale W, et al. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52. (Pubitemid 28277534)
30. Hung YH, Bush AI & Cherny RA (2010) Copper in the brain and Alzheimer's disease. J Biol Inorg Chem 15, 61-76.
31. Zecca L, Youdim MBH, Riederer P, et al. (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5, 863-873. (Pubitemid 39482155)
32. Morris MC, Evans DA, Tangney CC, et al. (2006) Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 63, 1085-1088. (Pubitemid 44232313)
33. Bucossi S, Ventriglia M, Panetta V, et al. (2010) Copper in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimer's Dis 23, 1-11.
34. Ellervik C, Birgens H, Tybjærg Hansen A, et al. (2007) Hemochromatosis genotypes and risk of 31 disease end-points: meta analyses including 66,000 cases and 226,000 controls. Hepatology 46, 1071-1080. (Pubitemid 350144771)
35. Jenagaratnam L & McShane R (2006) Clioquinol for the treatment of Alzheimer's Disease. Cochrane Database of Systematic Reviews issue 1, CD005380.
36. Sampson EL, Jenagaratnam L & McShane R (2008) Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database of Systematic Reviews issue 1, CD005380.
37. Kessler H, Bayer TA, Bach D, et al. (2008) Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. J Neural Transm 115, 1181-1187.
38. Kessler H, Pajonk FG, Bach D, et al. (2008) Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. J Neural Transm 115, 1651-1659.
39. Yaffe K, Clemons TE, McBee WL, et al. (2004) Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 63, 1705-1707. (Pubitemid 39507595)
40. Chandra RK (2001) Effect of vitamin and trace-element supplementation on cognitive function in elderly subjects. Nutrition 17, 709-712. (Pubitemid 32821143)
41. Gariballa S & Forster S (2007) Effects of dietary supplements on depressive symptoms in older patients: a randomised double-blind placebo-controlled trial. Clin Nutr 26, 545-551. (Pubitemid 47618321)
42. Planas M, Conde M, Audivert S, et al. (2004) Micronutrient supplementation in mild Alzheimer disease patients. Clin Nutr 23, 265-272. (Pubitemid 38401221)
43. McNeill G, Avenell A, Campbell M, et al. (2007) Effect of multivitamin and multimineral supplementation on cognitive function in men and women aged 65 years and over: a randomised controlled trial. Nutr J 6, 10.
44. Wouters-Wesseling W, Wagenaar L, Rozendaal M, et al. (2005) Effect of an enriched drink on cognitive function in frail elderly persons. J Gerontol A Biol Sci Med Sci 60, 265-270. (Pubitemid 40524870)
45. Ritchie C, Bush A, Mackinnon A, et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A {beta} amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691. (Pubitemid 37521621)
46. Lannfelt L, Blennow K, Zetterberg H, et al. (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurolo 7, 779-786.
47. Faux NG, Ritchie CW, Gunn A, et al. (2010) PBT2 Rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J Alzheimer's Dis 20, 509-516.
48. Squitti R, Rossini PM, Cassetta Ed-penicill, et al. (2002) lamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 32, 51-59. (Pubitemid 36228383)
49. McLachlan DR, Kruck TP, Kalow W, et al. (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308.
50. Squitti R, Bressi F, Pasqualetti P, et al. (2009) Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology 72, 50-55.
51. Milward EA, Bruce DG, Knuiman MW, et al. (2010) A cross-sectional community study of serum iron measures and cognitive status in older adults. J Alzheimer's Dis 20, 617-623.
52. Ortega RM, Requejo AM, Andrés P, et al. (1997) Dietary intake and cognitive function in a group of elderly people. Am J Clin Nutr 66, 803-809. (Pubitemid 27415562)
53. Lam P, Kritz-Silverstein D, Barrett-Connor E, et al. (2008) Plasma trace elements and cognitive function in older men and women: the Rancho Bernardo study. J Nutr Health Aging 12, 22-27. (Pubitemid 351156011)
54. Bartzokis G, Sultzer D, Cummings J, et al. (2000) In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 57, 47-53. (Pubitemid 30035658)
55. Rossi L, Squitti R, Pasqualetti P, et al. (2002) Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by-penicillamine. Neurosci Lett 329, 137-140. (Pubitemid 34880058)
56. Bartzokis G & Tishler TA (2000) MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-grand) 46, 821-833.
57. Bartzokis G, Tishler TA, Shin IL, et al. (2004) Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci 1012, 224-236. (Pubitemid 38453528)
58. Pankhurst Q, Hautot D, Khan N, et al. (2008) Increased levels of magnetic iron compounds in Alzheimer's disease. J Alzheimer's Dis 13, 49-52. (Pubitemid 351365627)
59. Kirsch W, McAuley G, Holshouser B, et al. (2009) Serial susceptibility weighted MRI measures brain iron and micro-bleeds in dementia. J Alzheimer's Dis 17, 599-609.
60. Ding B, Chen KM, Ling HW, et al. (2009) Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J Magn Reson Imaging 29, 793-798.
61. Basun H, Forssell LG, Wetterberg L, et al. (1991) Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 3, 231-258.
62. Vural H, Demirin H, Kara Y, et al. (2010) Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol 24, 169-173.
63. Molina JA, Jiménez-Jiménez FJ, Aguilar MV, et al. (1998) Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm 105, 479-488. (Pubitemid 28365030)
64. Hershey C, Hershey L, Varnes A, et al. (1983) Cerebrospinal fluid trace element content in dementia: clinical, radiologic, and pathologic correlations. Neurology 33, 1350-1352.
65. Loeffler D, DeMaggio A, Juneau P, et al. (1994) Ceruoplas-min is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis Assoc Disord 8, 190-197. (Pubitemid 24282548)
66. Kuiper MA, Mulder C, Van Kamp GJ, et al. (1994) Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. J Neural Transm Park Dis Dement Sect 7, 109-114.
67. Pulliam JF, Jennings CD, Kryscio RJ, et al. (2003) Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet 119, 48-53. (Pubitemid 37064053)
68. Moalem S, Percy ME, Andrews DF, et al. (2000) Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 93, 58-66. (Pubitemid 30350273)
69. Sampietro M, Caputo L, Casatta A, et al. (2001) The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 22, 563-568. (Pubitemid 32607740)
70. Guerreiro RJ, Bras JM, Santana I, et al. (2006) Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol 6, 24.
71. Berlin D, Chong G, Chertkow H, et al. (2004) Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging 25, 465-474. (Pubitemid 38317344)
72. Candore G, Licastro F, Chiappelli M, et al. (2003) Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy. Mech Ageing Dev 124, 525-528. (Pubitemid 36514908)
73. Zambenedetti P, De Bellis GL, Biunno I, et al. (2003) Trans-ferrin C2 variant does confer a risk for Alzheimer's disease in Caucasians. J Alzheimer's Dis 5, 423-427. (Pubitemid 38101229)
74. Squitti R, Lupoi D, Pasqualetti P, et al. (2002) Elevation of serum copper levels in Alzheimer's disease. Neurology 59, 1153-1161. (Pubitemid 35192384)
75. Squitti R, Pasqualetti P, Dal Forno G, et al. (2005) Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64, 1040-1046. (Pubitemid 40388458)
76. Squitti R, Barbati G, Rossi L, et al. (2006) Excess of noncer-uloplasmin serum copper in AD correlates with MMSE, CSF beta-amyloid, and h-tau. Neurology 67, 76-82. (Pubitemid 44305465)
77. Zappasodi F, Salustri C, Babiloni C, et al. (2008) An observational study on the influence of the APOE-epsilon4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res 1215, 183-189.
78. Brewer GJ, Kanzer SH, Zimmerman EA, et al. (2010) Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am J Alzheimer's Dis Other Demen 25, 490-497.
79. Agarwal R, Kushwaha SS, Tripathi CB, et al. (2008) Serum copper in Alzheimer's disease and vascular dementia. Ind J Clin Biochem 23, 369-374.
80. Smorgon C, Mari E, Atti A, et al. (2004) Trace elements and cognitive impairment: an elderly cohort study. Arch Gerontol Geriatr 393-402. (Pubitemid 38822890)
81. Snaedal J, Kristinsson J, Gunnarsdottir S, et al. (2000) Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9, 239-242.
82. Jeandel C, Nicolas MB, Dubois F, et al. (1989) Lipid peroxi-dation and free radical scavengers in Alzheimer's disease. Gerontology 35, 275-282. (Pubitemid 20015238)
83. Gonzalez C, Martin T, Cacho J, et al. (1999) Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon4 apolipoprotein E allele carriers. Eur J Clin Invest 29, 637-642. (Pubitemid 29322377)
84. Squitti R, Ventriglia M, Barbati G, et al. (2007) 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm 114, 1589-1594. (Pubitemid 350212005)
85. Kim KW, Jhoo JH, Lee JH, et al. (2001) Transferrin C2 variant does not confer a risk for Alzheimer's disease in Koreans. Neurosci Lett 308, 45-48. (Pubitemid 32607677)
86. Rondeau V, Iron A, Letenneur L, et al. (2006) Analysis of the effect of aluminum in drinking water and transferrin C2 allele on Alzheimer's disease. Eur J Neurol 13, 1022-1025. (Pubitemid 44284912)
87. Blázquez L, De Juan D, Ruiz-Martínez J, et al. (2007) Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population. Neurobiol Aging 28, 1941-1943. (Pubitemid 47539694)
88. Lleo A, Blesa R, Angelopoulos C, et al. (2002) Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease. Br Med J 72, 820-821. (Pubitemid 34557037)
89. Kauwe JS, Bertelsen S, Mayo K, et al. (2010) Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. Am J Med Genet B Neurop-sychiatr Genet 153, 955-959.
90. Robson KJ, Lehmann DJ, Wimhurst VL, et al. (2004) Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet 41, 261-265. (Pubitemid 38496768)
91. Zhang P, Yang Z, Zhang C, et al. (2003) Association study between late-onset Alzheimer's disease and the transferrin gene polymorphisms in Chinese. Neurosci Lett 349, 209-211. (Pubitemid 37297814)
92. Shore D, Henkin R, Nelson N, et al. (1984) Hair and serum copper, zinc, calcium, and magnesium concentrations in Alzheimer-type dementia. J Am Geriatr Soc 32, 892-895. (Pubitemid 15222171)
93. Squitti R, Ghidoni R, Scrascia F, et al. (2011) Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimer's Dis 23, 239-248.
94. Arnal N, Cristalli DO, de Alaniz MJ, et al. (2010) Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res 1319, 118-130.
95. Babiloni C, Squitti R, Del Percio C, et al. (2007) Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimer's disease subjects. Clin Neurophysiol 118, 1244-1260. (Pubitemid 46736024)
96. Ozcankaya R & Delibas N (2002) Malondialdehyde, super-oxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J 43, 28-32. (Pubitemid 34157862)
97. Squitti R, Salustri C, Siotto M, et al. (2010) Ceruloplasmin/transferrin ratio changes in Alzheimer's disease. Int J Alzhei-mers Dis 2011, 231595.
98. Squitti R, Quattrocchi CC, Forno GD, et al. (2007) Cerulo-plasmin (2-D PAGE) pattern and copper content in serum and brain of Alzheimer disease patients. Biomark Insights 1, 205-213.
99. Deibel MA, Ehmann WD & Markesbery WR (1996) Copper, iron, and zinc imbalances in severly degenerated brain regions in Alzheimer's disease: possible relation to oxi-dative stress. J Neurol Sci 143, 137-142. (Pubitemid 26402800)
100. Smith MA, Harris PL, Sayre LM, et al. (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94, 9866-9868. (Pubitemid 27408156)
101. Sayre LM, Perry G, Harris PL, et al. (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74, 270-279. (Pubitemid 30012778)
102. Loeffler DA, Connor JR, Juneau PL, et al. (1995) Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 65, 710-716.
103. Connor J, Menzies S, Martin S, et al. (1992) A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 31, 75-83.
104. Connor JR, Snyder BS, Beard JL, et al. (1992) Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 31, 327-335.
105. House MJ, St Pierre TG & McLean C (2008) 1·4T study of proton magnetic relaxation rates, iron concentrations, and plaque burden in Alzheimer's disease and control postmortem brain tissue. Magn Reson Med 60, 41-52. (Pubitemid 351956608)
106. Leite RE, Jacob-Filho W, Saiki M, et al. (2008) Determination of trace elements in human brain tissues using neutron activation analysis. J Radioanal Nucl Chem 278, 581-584.
107. Panayi AE, Spyrou NM, Ubertalli LC, et al. (2000) Differences in trace element concentrations between the right and left hemispheres of human brain using INAA. J Radioanal Nucl Chem 244, 205-207. (Pubitemid 30456638)
108. Andrási E, Farkas É, Gawlik D, et al. (2000) Brain iron and zinc contents of German patients with Alzheimer disease. J Alzheimer's Dis 2, 17-26. (Pubitemid 30353514)
109. Samudralwar DL, Diprete CC, Ni BF, et al. (1995) Elemental imbalances in the olfactory pathway in Alzheimer's disease. J Neurol Sci 130, 139-145.
110. Atamna H & Frey WH 2nd (2004) A role for heme in Alzheimer's disease: heme binds amyloid and has altered metabolism. Proc Natl Acad Sci USA 101, 11153-11158. (Pubitemid 38989599)
111. Jellinger K, Paulus W, Grundke-Iqbal I, et al. (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 2, 327-340.
112. Grundke-Iqbal I, Fleming J, Tung YC, et al. (1990) Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol (Berl) 81, 105-110.
113. Smith M, Wehr K, Harris P, et al. (1998) Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res 788, 232-236. (Pubitemid 28202166)
114. Corrigan FM, Reynolds GP & Ward NI (1993) Hippocampal tin, aluminum and zinc in Alzheimer's disease. BioMetals 6, 149-154.
115. Ward NI & Mason JA (1987) Neutron activation analysis techniques for identifying elemental status in Alzheimer's disease. J Radioanal Nucl Chem 113, 515-526. (Pubitemid 18053924)
116. Andrási E, Farkas É, Scheibler H, et al. (1995) Al, Zn, Cu, Mn and Fe levels in brain in Alzheimer's disease. Arch Gerontol Geriatr 21, 89-97.
117. Plantin LO, Lying-Tunell U & Kristensson K (1987) Trace elements in the human central nervous system studied with neutron activation analysis. Biol Trace Elem Res 13, 69-75.
118. Tandon L, Ni BF, Ding XX, et al. (1994) RNAA for arsenic, cadmium, copper, and molybdenum in CNS tissues from subjects with age-related neurodegenerative diseases. J Radioanal Nucl Chem 179, 331-339. (Pubitemid 24182325)
119. Loeffler DA, LeWitt PA, Juneau PL, et al. (1996) Increased regional brain concentrations of ceruloplasmin in neurode-generative disorders. Brain Res 738, 265-274. (Pubitemid 26378921)
120. Castellani RJ, Smith MA, Nunomura A, et al. (1999) Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med 26, 1508-1512. (Pubitemid 29302284)
121. Lovell MA, Robertson JD, Teesdale WJ, et al. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52. (Pubitemid 28277534)
122. Miller LM, Wang Q, Telivala TP, et al. (2006) Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J Struct Biol 155, 30-37. (Pubitemid 43867313)
123. Connor JR, Snyder BS, Arosio P, et al. (1995) A quantitative analysis of isoferritins in select regions of aged, parkinso-nian, and Alzheimer's diseased brains. J Neurochem 65, 717-724.
124. Cornett CR, Markesbery WR & Ehmann WD (1998) Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19, 339-345.
125. Cornett CR, Ehmann WD, Wekstein DR, et al. (1998) Trace elements in Alzheimer's disease pituitary glands. Biol Trace Elem Res 62, 107-114. (Pubitemid 28246538)
126. Connor JR, Tucker P, Johnson M, et al. (1993) Ceruloplas-min levels in the human superior temporal gyrus in aging and Alzheimer's disease. Neurosci Lett 159, 88-90. (Pubitemid 23283245)
127. Landeghem GF, Sikström C, Beckman LE, et al. (1998) Transferrin C2, metal binding and Alzheimer's disease. Neuroreport 9, 177-179. (Pubitemid 28081384)
128. Van Rensburg SJ, Carstens ME, Potocnik FC, et al. (1993) Increased frequency of the transferrin C2 subtype in Alzheimer's disease. Neuroreport 4, 1269-1271. (Pubitemid 23289210)
129. Kessler H, Pajonk FG, Meisser P, et al. (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. J Neural Transm 113, 1763-1769. (Pubitemid 44657672)
130. Pajonk FG, Kessler H, Supprian T, et al. (2005) Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J Alzheimer's Dis 8, 23-27. (Pubitemid 41267320)
131. Salustri C, Barbati G, Ghidoni R, et al. (2010) Is cognitive function linked to serum free copper levels A cohort study in a normal population. Clin Neurophysiol 121, 502-507.
132. Squitti R, Cassetta E, Dal Forno G, et al. (2004) Copper perturbation in 2 monozygotic twins discordant for degree of cognitive impairment. Arch Neurol 61, 738-743. (Pubitemid 38637692)
133. Hampel H, Frank R, Broich K, et al. (2010) Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574.
134. Regland B, Lehmann W, Abedini I, et al. (2000) Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 12, 408-414. (Pubitemid 34701665)
135. Martell AE & Smith RM (1974) Critical Stability Constants. New York, NY: Plenum Press.
136. Religa D, Strozyk D, Cherny RA, et al. (2006) Elevated cortical zinc in Alzheimer disease. Neurology 67, 69-75. (Pubitemid 44305464)
137. Bomford A (2002) Genetics of haemochromatosis. Lancet 360, 1673-1681. (Pubitemid 35379742)
138. Ponka P, Beaumont C & Richardson DR (1998) Function and regulation of transferrin and ferritin. Semin Hematol 35, 35-54. (Pubitemid 28047041)
139. Squitti R, Lupoi D, Pasqualetti P, et al. (2002) Elevation of serum copper levels in Alzheimer's disease. Neurology 59, 1153-1161. (Pubitemid 35192384)
140. Squitti R, Pasqualetti P, Dal Forno G, et al. (2005) Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64, 1040-1046. (Pubitemid 40388458)
141. Agarwal R, Kushwaha S, Tripathi C, et al. (2008) Serum copper in Alzheimer's disease and vascular dementia. Ind J Clin Biochem 23, 369-374.
142. Zappasodi F, Salustri C, Babiloni C, et al. (2008) An observational study on the influence of the APOE-[epsilon] 4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res 1215, 183-189.
143. Squitti R, Barbati G, Rossi L, et al. (2006) Excess of noncer-uloplasmin serum copper in AD correlates with MMSE, CSF {beta}-amyloid, and h-tau. Neurology 67, 76-82. (Pubitemid 44305465)
144. Shore D, Henkin RI, Nelson NR, et al. (1984) Hair and serum copper, zinc, calcium, and magnesium concentrations in Alzheimer-type dementia. J Am Geriatr Soc 32, 892-895. (Pubitemid 15222171)
145. Haan MN, Shemanski L, Jagust WJ, et al. (1999) The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282, 40-46. (Pubitemid 29318931)
146. Fotuhi M, Mohassel P & Yaffe K (2009) Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 5, 140-152.
147. Sparks DL, Petanceska S, Sabbagh M, et al. (2005) Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res 2, 527-539. (Pubitemid 41709390)
148. Petersen RC, Smith GE, Waring SC, et al. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
149. House MJ, St Pierre TG, Milward EA, et al. (2010) Relationship between brain R(2) and liver and serum iron concentrations in elderly men. Magn Reson Med 63, 275-281.
150. Deibel M, Ehmann W & Markesbery W (1996) Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 143, 137-142. (Pubitemid 26402800)
151. Schrag M, Dickson A, Jiffry A, et al. (2010) The effect of formalin fixation on the levels of brain transition metals in archived samples. Biometals 23, 1123-1127.
152. Bayer T, Schäfer S, Simons A, et al. (2003) Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid A production in APP23 transgenic mice. Proc Natl Acad Sci USA 100, 14187-14192. (Pubitemid 37499212)
153. Borchardt T, Camakaris J, Cappai R, et al. (1999) Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem J 344, Pt 2, 461-467. (Pubitemid 30011603)
154. Multhaup G, Schlicksupp A, Hesse L, et al. (1996) The amyloid precursor protein of Alzheimer's disease in the reduction of copper (II) to copper (I). Science 271, 1406-1409. (Pubitemid 26089474)
155. Hung YH, Robb EL, Volitakis I, et al. (2009) Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions. J Biol Chem 284, 21899-21907.
156. Simons K & Ikonen E (1997) Functional rafts in cell membranes. Nature 387, 569-572. (Pubitemid 27248754)
157. Kong GK, Miles LA, Crespi GA, et al. (2008) Copper binding to the Alzheimer's disease amyloid precursor protein. Eur Biophys J 37, 269-279.
158. Ehehalt R, Keller P, Haass C, et al. (2003) Amyloidogenic processing of the Alzheimer-amyloid precursor protein depends on lipid rafts. J Cell Biol 160, 113-123. (Pubitemid 36091721)
159. Schneider A, Rajendran L, Honsho M, et al. (2008) Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J Neurosci 28, 2874-2882. (Pubitemid 351398889)
160. Armendariz AD, Gonzalez M & Loguinov AV (2004) Gene expression profiling in chronic copper overload reveals upregulation of Prnp and App. Physiol Genomics 20, 45-54. (Pubitemid 40388504)
161. Hayashi T, Shishido N, Nakayama K, et al. (2007) Lipid per-oxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free
162. Sparks DL & Schreurs BG (2003) Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA 100, 11065-11069. (Pubitemid 37140153)
163. Lin H, Bhatia R & Lal R (2001) Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J 15, 2433-2444. (Pubitemid 33063171)
164. Curtain CC, Ali FE, Smith DG, et al. (2003) Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J Biol Chem 278, 2977-2982. (Pubitemid 36801204)
165. Ghribi O, Golovko MY, Larsen B, et al. (2006) Deposition of iron and amyloid plaques is associated with cortical cellular damage in rabbits fed with long term cholesterol enriched diets. J Neurochem 99, 438-449. (Pubitemid 44477201)
166. Keys A, Anderson JT & Grande F (1965) Serum cholesterol response to changes in the diet: IV. Particular saturated fatty acids in the diet. Metabolism 14, 776-787.
167. Hegsted DM, McGandy RB, Myers ML, et al. (1965) Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr 17, 281-295.
168. Mensink RP & Katan MB (1992) Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 12, 911-919.
169. Gu Y, Nieves JW, Stern Y, et al. (2010) Food combination and Alzheimer disease risk. Arch Neurol 67, 699-706.
170. Dwyer BE, Zacharski LR, Balestra DJ, et al. (2010) Potential role of iron in a Mediterranean-style diet. Arch Neurol 67, 1286-1288.
171. Buijsse B, Feskens EJ, Moschandreas J, et al. (2007) Oxidative stress, and iron and antioxidant status in elderly men: differences between the Mediterranean south (Crete) and northern Europe (Zutphen). Eur J Cardiovasc Prev Rehabil 14, 495-500. (Pubitemid 47229728)
172. Willett WC, Sacks F, Trichopoulou A, et al. (1995) Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr 61, 1402S-1406S.
173. Lindow CW, Elvehjem CA & Peterson WH (1929) The copper content of plant and animal foods. J Biol Chem 82, 465-471.
174. Lurie DG, Holden JM, Schubert A, et al. (1989) The copper content of foods based on a critical evaluation of published analytical data. J Food Compos Anal 2, 298-316.
175. Solomons N (1979) On the assessment of zinc and copper nutriture in man. Am J Clin Nutr 32, 856-871. (Pubitemid 9164734)
176. Akiyama H, Barger S, Barnum S, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421. (Pubitemid 30349107)
177. Dunlap WM, James GW & Hume DM (1974) Anemia and neutropenia caused by copper deficiency. Ann Intern Med 80, 470-476.
178. Looker AC, Dallman PR, Carroll MD, et al. (1997) Prevalence of iron deficiency in the United States. JAMA 277, 973-976. (Pubitemid 27142364)
179. What we eat in America, NHANES 2007-2008 (database on the Internet) 2007-2008 http://www.ars.usda.gov/SP2UserFiles/Place/12355000/pdf/0708/Table-1- NIN-GEN-07.pdf (cited Nov 26th 2010)
180. National Academy of Sciences (2004) Dietary reference tables http://iom.edu/en/Global/News%20Announce-ments/,/media/Files/Activity%20Files/ Nutrition/DRIs/DRISummaryListing2.ashx (cited 2010 Nov 25)
181. Lee JY, Friedman JE, Angel I, et al. (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 25, 1315-1321. (Pubitemid 39299169)
182. Amit T, Avramovich-Tirosh Y, Youdim MB, et al. (2008) Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 22, 1296-1305. (Pubitemid 351656771)
183. Mandel S, Amit T, Bar-Am O, et al. (2007) Iron dysregula-tion in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurores-cue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol 82, 348-360. (Pubitemid 47126678)
184. Weinreb O, Mandel S, Amit T, et al. (2004) Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem 15, 506-516. (Pubitemid 39209392)
185. Jiao Y, Wilkinson J 4th, Christine Pietsch E, et al. (2006) Iron chelation in the biological activity of curcumin. Free Radic Biol Med 40, 1152-1160.
186. Baum L & Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimer's Dis 6, 367-377. (Pubitemid 39287248)
187. McGeer PL, Schulzer M & McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425-432. (Pubitemid 26324038)
188. Malecki EA & Connor JR (2002) The case for iron chelation and/or antioxidant therapy in Alzheimer's disease. Drug Dev Res 56, 526-530. (Pubitemid 35168328)
189. Dwyer BE, Zacharski LR, Balestra DJ, et al. (2009) Getting the iron out: phlebotomy for Alzheimer's disease? Med Hypotheses 72, 504-509.